True North Labs

Author: labstruenorth@gmail.com

  • ComboMATCH Screening Trial Opens New Doors for Precision Cancer Treatment

    ComboMATCH Screening Trial Opens New Doors for Precision Cancer Treatment

    A promising new clinical trial initiative called ComboMATCH is now underway, offering a fresh approach to treating patients with locally advanced or advanced solid tumors. Rather than relying on a one-size-fits-all treatment plan, this screening trial uses genetic testing to identify specific mutations within a patient’s tumor, then works to match that patient with a targeted therapy combination designed to address those particular genetic changes.

    The trial is specifically designed for patients whose cancer has progressed despite prior treatment, or for whom no standard therapy has been shown to extend survival — a population that often has limited options. By serving as a screening gateway to a broader network of coordinated clinical trials, ComboMATCH aims to streamline the process of connecting these patients with therapies that are more likely to be effective based on their tumor’s unique genetic profile.

    This approach reflects the growing momentum behind precision oncology, a field built on the idea that understanding the genetic drivers of a tumor can lead to smarter, more personalized treatment decisions. Instead of guessing which therapy might work, doctors can use genetic data to guide their choices, potentially improving outcomes while also helping researchers learn more about which mutations respond best to which combination treatments.

    What makes ComboMATCH especially encouraging is its scale and structure. By functioning as a centralized screening effort feeding into multiple downstream studies, it creates a more efficient pathway for matching patients to appropriate trials, reducing time and uncertainty for people who may have already tried multiple treatment approaches. This kind of coordinated infrastructure represents a meaningful step forward in how the research community organizes and delivers genetically-informed cancer care.

    For patients and families navigating advanced solid tumors, initiatives like ComboMATCH offer a hopeful glimpse into the future of oncology — one where treatment decisions are increasingly guided by the specific biology of a person’s cancer rather than broad categories of disease. As this trial and its associated studies progress, they may help expand the range of options available to patients who need them most.

    This article is for informational purposes only and is not intended as medical advice. Patients interested in clinical trials should speak with their healthcare provider.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Asahi Kasei Advances Novel Peptide Candidate Into Phase I Trial for Autoimmune Diseases

    Asahi Kasei, a major Japanese chemical and pharmaceutical company, has announced the initiation of a Phase I clinical trial for a novel peptide candidate designed to target autoimmune diseases. This marks an important early milestone in the development pipeline, as the company moves its peptide-based therapeutic approach from preclinical research into human testing.

    Autoimmune diseases, which occur when the immune system mistakenly attacks the body’s own tissues, affect millions of people worldwide and often require long-term management. The development of new peptide-based therapies represents a growing area of interest in medicine, as peptides can be designed to interact with specific biological pathways with a high degree of precision, potentially offering more targeted treatment options compared to broader immunosuppressive therapies.

    Phase I trials are the first stage of testing in humans and are primarily focused on evaluating the safety, tolerability, and dosing of a new candidate. While it is still early in the development process, the initiation of this trial reflects meaningful progress from laboratory research toward a therapy that could one day benefit patients living with autoimmune conditions.

    Asahi Kasei’s move into clinical testing also highlights the broader momentum in the peptide therapeutics field, where pharmaceutical companies continue to explore innovative molecules for conditions that have historically been difficult to treat. Successful early-stage trials often pave the way for larger studies that further examine efficacy and long-term safety.

    As this trial progresses, the peptide research community will be watching closely for updates on safety data and any signals of therapeutic potential. This is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases – BioSpace

  • Lilly’s Retatrutide Hits Major Milestone: Phase 3 Trial Shows Significant Weight Loss and Osteoarthritis Pain Relief

    Eli Lilly has announced encouraging results from the first successful Phase 3 trial of retatrutide, an investigational triple agonist peptide designed to target three key metabolic hormone receptors simultaneously. The trial reported an average weight loss of up to 71.2 pounds among participants, marking one of the most substantial results seen yet in this rapidly evolving class of metabolic therapies.

    What makes this trial particularly notable is that it didn’t just measure weight loss. Researchers also tracked improvements in osteoarthritis-related joint pain, and participants experienced substantial relief on that front as well. Osteoarthritis is a condition often exacerbated by excess body weight, particularly in weight-bearing joints like the knees and hips, so the dual benefit suggests retatrutide may offer meaningful quality-of-life improvements that extend beyond the scale.

    Retatrutide works by engaging three separate receptor pathways: GLP-1, GIP, and glucagon. This triple-action approach builds on the success of earlier dual-agonist and single-agonist peptides already available for weight management and metabolic health, and researchers have been optimistic that hitting multiple pathways at once could unlock even greater benefits for patients struggling with obesity and related conditions.

    This successful Phase 3 result is an important step toward potential regulatory review and, eventually, broader access for patients. Positive Phase 3 outcomes are typically the last major clinical hurdle before a therapy can be submitted for approval, so this milestone brings retatrutide meaningfully closer to becoming available to the people who might benefit from it most.

    For the peptide research and metabolic health community, this trial represents another encouraging sign that the next generation of these therapies may deliver even more comprehensive benefits, addressing not just weight but the painful joint conditions that so often accompany excess weight. As Lilly continues to move through the clinical and regulatory process, many will be watching closely for further data and next steps.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance specific to your situation.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial – Eli Lilly

  • New Clinical Trial Explores Optimal Timing for Vasopressin in Septic Shock Care

    New Clinical Trial Explores Optimal Timing for Vasopressin in Septic Shock Care

    A promising new clinical trial registered on ClinicalTrials.gov is set to investigate how the timing of vasopressin administration might improve care for patients experiencing septic shock, a life-threatening condition that affects thousands of critically ill patients each year. The CASPER-Pilot study represents an innovative approach that combines peptide-based therapy with cutting-edge digital health tools.

    Vasopressin, a naturally occurring peptide hormone, is already used as a supportive treatment alongside norepinephrine to help stabilize blood pressure in patients with septic shock. What makes this study particularly exciting is its use of clinical decision support (CDS) technology built directly into the Epic electronic health record system. Researchers aim to use this technology to help identify and randomize patients into two groups—one receiving earlier vasopressin initiation and one following standard of care—based on their norepinephrine dosing needs.

    This approach reflects a growing trend in medicine: leveraging smart technology to refine and personalize the use of established peptide therapies. By creating clearly defined patient cohorts based on precise clinical triggers, the study hopes to generate reliable data on whether earlier use of this peptide hormone could lead to better outcomes for critically ill patients. The pilot nature of the study also means researchers are laying important groundwork, testing not just clinical outcomes but also how well the decision-support technology performs in real-world hospital settings.

    If successful, this research could pave the way for more efficient, technology-assisted protocols for administering vasopressin and potentially other peptide-based interventions in emergency and critical care settings. Streamlining the decision-making process around when to introduce adjunctive therapies like vasopressin could help clinicians act more quickly and consistently, which is often crucial in fast-moving conditions like septic shock.

    As this pilot study progresses, it offers a hopeful glimpse into how combining established peptide therapies with modern health information technology may enhance patient care. True North Labs will continue to follow developments in this space as more data becomes available.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Early Versus Late Adjunctive Vasopressin in Septic Shock

  • New Clinical Trial Aims to Identify the Best Treatment for a Rare Autoimmune Disease

    New Clinical Trial Aims to Identify the Best Treatment for a Rare Autoimmune Disease

    A newly launched clinical trial is set to bring much-needed clarity to the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare and serious autoimmune condition that can cause vision loss, paralysis, and severe pain by attacking the eyes and spinal cord. Rather than testing a single new drug, this study takes a valuable head-to-head approach, comparing five medications that are already FDA-approved: rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab.

    The trial will enroll 160 adults who test positive for the AQP4-IgG antibody, a key marker used to diagnose this form of NMOSD. Participants will be randomly assigned to receive rituximab or one of the four other approved therapies, allowing researchers to directly measure which treatments are most effective at preventing relapses and which carry the fewest serious side effects. This kind of comparative research is especially useful for patients and physicians, since it can be difficult to know which of several approved options is the best fit without solid, side-by-side evidence.

    Beyond simply tracking relapses, the study takes a thorough, patient-centered approach. Researchers will monitor disability progression, quality of life, and patient satisfaction, alongside biomarkers that help reveal how active the disease is beneath the surface. Regular assessments will include vision tests, walking evaluations, and checks on brain function, giving a well-rounded picture of how each treatment affects daily life and long-term health, not just clinical measures.

    With follow-up spanning one to four years per participant, the trial is designed to generate durable, meaningful data rather than quick snapshots. For a condition as rare and potentially disabling as NMOSD, this kind of rigorous, long-term comparison could be a significant step forward, helping doctors move beyond guesswork and toward evidence-based decisions tailored to individual patients.

    Ultimately, this research reflects a broader and encouraging trend in rare disease care: using existing approved therapies more wisely by understanding exactly how they stack up against one another. If successful, the trial could help streamline treatment decisions, reduce trial-and-error prescribing, and improve outcomes for people living with this challenging condition.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

  • New Clinical Trial Explores Bevacizumab to Reduce Surgeries for Recurrent Respiratory Papillomatosis

    New Clinical Trial Explores Bevacizumab to Reduce Surgeries for Recurrent Respiratory Papillomatosis

    Recurrent respiratory papillomatosis (RRP) is a challenging rare condition in which wart-like growths repeatedly form in the airway, often requiring patients to undergo multiple surgeries each year just to keep breathing passages clear. A newly launched clinical trial is now investigating whether a well-known therapeutic, bevacizumab, could offer meaningful relief by reducing how often these surgeries are needed.

    The study, open to adults 18 and older who require surgery for RRP, is designed to carefully evaluate both the safety and potential benefit of bevacizumab as a follow-up treatment after surgical removal of airway growths. Participants will first undergo thorough evaluations, including breathing and voice assessments, endoscopy, heart function testing, and chest imaging, ensuring that treatment is tailored and monitored closely throughout the study.

    Following surgery, participants will receive a structured series of 11 bevacizumab infusions, administered on a tapering schedule, first every three weeks and then every six weeks. This approach allows researchers to closely track how the treatment affects recurrence of the growths over time. Tissue samples collected during the study will also give scientists valuable insight into how RRP growths respond to bevacizumab at a cellular level, which could inform future treatment refinements.

    What makes this trial especially encouraging is its direct focus on quality of life. Because RRP can require frequent, invasive procedures, any therapy that lessens the surgical burden could greatly improve patients’ day-to-day lives, reducing time spent in operating rooms and recovery, along with the associated risks and costs of repeated surgery. Bevacizumab, which works by targeting blood vessel growth that tumors and papillomas rely on, has shown promise in various other conditions, making this investigation a logical and hopeful next step for RRP patients.

    With follow-up continuing for a full year after the final treatment, researchers will be able to assess longer-term outcomes and durability of any benefits observed. While results are not yet available, the initiation of this well-structured trial marks a meaningful step forward for a patient community that has long awaited more effective, less invasive treatment options. As research progresses, findings from this study could help shape future protocols for managing RRP and easing the burden of this chronic condition.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

  • FDA Signals Support for Peptides Following Extensive Review

    In a development that peptide researchers, compounding pharmacists, and patients have been watching closely, the FDA has reportedly voted in favor of peptides following a lengthy deliberation process. While the specifics of the review are still being detailed in follow-up reporting, the outcome itself is a welcome sign for a category of therapeutics that has grown rapidly in both clinical and wellness applications over the past several years.

    Peptides occupy a unique space in modern medicine. Because many of them are short chains of amino acids that mimic naturally occurring biological signals, they have found use in areas ranging from metabolic health to tissue repair to hormone regulation. As interest in these compounds has expanded, so has scrutiny from regulators tasked with ensuring that manufacturing, labeling, and distribution meet appropriate safety and quality standards. A favorable vote after such an extensive review suggests that regulators found sufficient basis to support continued or expanded availability of these compounds through appropriate channels.

    For patients who rely on compounded peptide therapies, and for the clinicians who prescribe them, regulatory clarity is often just as valuable as the science itself. Lengthy deliberation processes, while sometimes frustrating for stakeholders awaiting a decision, typically indicate that regulators are weighing input from multiple angles, including manufacturing quality, clinical evidence, and public health considerations. A vote in favor after this kind of careful process can offer a stronger foundation of confidence than a hasty ruling might.

    This kind of regulatory outcome also matters for the broader peptide research and development ecosystem. Companies investing in new peptide-based therapies, as well as academic researchers studying their mechanisms, benefit from a regulatory environment that is engaged and willing to support well-founded uses of these molecules. It can encourage further investment in quality manufacturing practices and rigorous clinical study, both of which ultimately serve patient safety and therapeutic innovation.

    As more details emerge about the scope and implications of this FDA decision, True North Labs will continue to follow the story and share updates relevant to the peptide community. In the meantime, this development stands as a positive signal for the continued availability and legitimacy of peptide-based approaches within the healthcare system. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Votes in Favor of Peptides After Lengthy Deliberation – Drug Topics

  • Personalized Neoantigen DNA Vaccine Shows Promise in Early Glioblastoma Trial

    Personalized Neoantigen DNA Vaccine Shows Promise in Early Glioblastoma Trial

    Researchers have reported encouraging early results from a Phase 1 clinical trial testing a personalized, multivalent neoantigen DNA vaccine designed as an adjuvant therapy for patients with MGMT-unmethylated glioblastoma—a particularly aggressive brain cancer subtype known for its resistance to standard chemotherapy. The findings, published in Nature, mark an important step forward in the search for more effective treatment options for this challenging diagnosis.

    Unlike one-size-fits-all treatments, this approach uses each patient’s own tumor genetics to design a custom DNA vaccine targeting multiple neoantigens—unique protein markers that arise from mutations specific to that individual’s cancer. By training the immune system to recognize several of these distinct markers at once, researchers hope to reduce the chance that the tumor can evade detection, a common challenge in cancer immunotherapy.

    As a Phase 1 trial, the primary goals were to establish safety and feasibility, and the results on this front appear promising. The personalized vaccine approach was successfully manufactured and administered to patients, demonstrating that this highly individualized strategy can move from concept to clinic in a real-world trial setting. Importantly, the study also provides early evidence of the vaccine’s ability to stimulate meaningful immune activity, a critical first signal that this strategy may help the body’s own defenses engage with the tumor.

    Glioblastoma remains one of the most difficult cancers to treat, and the MGMT-unmethylated subtype has historically shown limited response to existing therapies, making the need for innovative options especially urgent. The use of personalized neoantigen vaccines reflects a broader and growing trend in oncology: leveraging genetic sequencing and immune-targeting technology to create tailored treatments rather than relying solely on standardized regimens. Early-phase trials like this one are essential building blocks, offering researchers critical data on safety and immune response that will inform the design of larger studies.

    While much work remains before this approach could become a standard treatment option, this trial represents a meaningful and hopeful advance in applying personalized peptide- and DNA-based vaccine technology to one of neuro-oncology’s toughest challenges. Continued research and larger controlled trials will be needed to determine how this strategy affects long-term outcomes. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial – Nature

  • Understanding Peptides: How They’re Shaping Medicine, Skincare, and Wellness

    Peptides have moved from a niche topic in biochemistry labs to a familiar term in medicine cabinets and skincare aisles alike. These short chains of amino acids, which serve as the building blocks of proteins, are increasingly recognized for their diverse and beneficial roles in the body—from supporting tissue repair to regulating hormones and immune responses.

    In medicine, peptide-based therapies have already made a meaningful impact. Several peptide drugs are FDA-approved and used to manage conditions such as diabetes, osteoporosis, and certain hormonal imbalances. Their ability to mimic naturally occurring biological signals allows them to interact with the body in targeted ways, often with fewer off-target effects compared to broader-acting drugs. This precision is part of why researchers and clinicians continue to explore new therapeutic applications for peptides across a range of health conditions.

    Beyond prescription medicine, peptides have also become a staple ingredient in skincare formulations. Topical peptides are frequently included in serums and creams aimed at supporting collagen production and improving skin texture. While results can vary by individual and formulation, the growing consumer interest reflects broader recognition of peptides’ potential to support skin health as part of a well-rounded skincare routine.

    In the wellness space, interest in peptides has expanded to include areas like recovery, sleep support, and general vitality. This growing curiosity has helped drive further scientific interest, encouraging more research into how different peptides function and how they might be used safely and effectively. As understanding deepens, this ongoing research helps separate well-supported uses from areas still needing more investigation.

    Overall, the expanding presence of peptides across medicine, skincare, and wellness highlights their versatility and the promise they hold for future innovation. As research continues, consumers and patients alike may benefit from clearer guidance on how peptides can be safely incorporated into health and beauty routines. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Peptide Uses: Medicine, Skincare, Wellness, and More – GoodRx

  • FDA Approves Rusfertide (MIMRYLO™), a Hepcidin-Mimetic Peptide, for Polycythemia Vera

    FDA Approves Rusfertide (MIMRYLO™), a Hepcidin-Mimetic Peptide, for Polycythemia Vera

    Protagonist Therapeutics has announced that the U.S. Food and Drug Administration has approved MIMRYLO™ (rusfertide), a hepcidin-mimetic peptide, for the treatment of polycythemia vera. This approval represents a significant milestone for peptide-based therapeutics entering mainstream clinical use for hematologic conditions.

    Polycythemia vera is a rare blood disorder characterized by the overproduction of red blood cells, which can lead to increased risk of blood clots and other complications. Rusfertide works by mimicking hepcidin, a naturally occurring hormone that plays a central role in regulating iron metabolism and, in turn, red blood cell production. By harnessing this natural regulatory pathway, the peptide offers a targeted approach to helping manage the disease.

    The approval of MIMRYLO™ underscores the growing recognition of peptide therapeutics as viable, precision-based treatment options across a range of medical conditions. Hepcidin mimetics like rusfertide represent an innovative class of therapies that work with the body’s own regulatory systems rather than against them, potentially offering patients a more physiologically aligned treatment approach compared to some traditional therapies.

    For the polycythemia vera patient community, this approval provides an additional tool for physicians to consider when developing treatment plans. The development also highlights the continued momentum in peptide drug discovery, as researchers and companies increasingly look to naturally occurring peptide hormones as templates for new medicines addressing previously difficult-to-treat conditions.

    This news reflects the broader positive trajectory of peptide-based medicine, where scientific understanding of the body’s own signaling molecules continues to translate into new, approved treatment options. As always, patients should discuss any treatment decisions with their qualified healthcare providers. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera – The Joplin Globe